popular guideline is believed to be ADA(American Diabetic Association) but in practice much variation is seen from the initiation (selection of drugs). There is no comparative analytical report between followers and non-followers of guideline about outcome.
Initial treatment of patients with T2DM includes education, with emphasis on lifestyle changes including diet, exercise and weight reduction when appropriate. Monotherapy with metformin is indicated for most patients and insulin may be indicated for initial treatment for some. 8 Although several studies have noted remissions of T2DM, that may last several years, most patients probably require continuous treatment in order to maintain normal or near-normal glycemia. Regardless of the initial drug and response to therapy, the natural history of most patients with T2DM is the deterioration of beta-cell function.
Most patients will need dual therapy to achieve target blood glucose and HbA1c. Choice of second agent is very vital. All the drugs are compared for their efficacy, safety, hypoglycemic risk, weight change, adverse effects as well as cost. After a successful initial response to oral therapy, patients fail to maintain target A1C levels (<7%) at a rate of 5 to 10 percent per year (UKPDS). An analysis from the United Kingdom Prospective Diabetes Study (UKPDS) found that 50 percent of patients originally controlled with a single drug required the addition of a second drug after three years; by nine years 75 percent of patients needed multiple therapies to achieve the target HbA1c value <7%. With treatment, monitoring and evaluation for micro-vascular and macro-vascular complications are to be assessed. 9 All patients eventually need insulin, in spite of T2DM, due to its progressive nature and gradual deterioration of beta cell function.
The consensus algorithm recommends testing HbA1c levels in every three months and addition of a second medication when the treatment goal of HbA1c <7% with metformin plus lifestyle intervention is not achieved within three months. 11 In order to achieve the glycaemicgoal, the following glucose goals are usually necessary: fasting glucose 70 to 130 mg/dL (3.89 to 7.22 mmol/l) and postprandial glucose (90 to 120 minutes after a meal) <180 mg/dL (10 mmol ). 11
ADA/EASD Guideline
In ADA/EASD guideline, it is ascribed as adopted for adult T2DM, non-pregnant, relatively healthy individual with mild to moderate hyperglycemia (newly detected DM), to start with and to maintain healthy lifestyle (Healthy eating, Weight control, Increased Physical Activity), start as monotherapy with metformin. Of course, they guided to consider, efficacy (HbA1c lowering capacity), hypoglycemia, weight, side effect and cost of the drug. Then if needed, to reach individual target of HbA1c after ~ 3 months, proceed to second line(2 Drug Combination). The choice of second drug is tricky. One can choice either of SU(Sulfonylurea), TZD(Thiazolidinedione), DPP4i( DPP IV Inhibitors), GLP-1RA(GLP-1 Receptor Agonist),BI (basal insulin); (eg. LS+Met+DPP4i). If this 2 drug regime fails to achieve HbA1c at target in next 3 months or to maintain it, add 3 rd agent from these 5 agents (eg. LS+Met+DPP4i+SU or LS+Met+DPP4i+bI).
For all patients consider to initiate dual therapy (2 drugs) when initial HbA1c >9.0% to more expeditiously achieve the target HbA1c. If weight loss or ketosis is present start insulin. Start insulin if HbA1c> 10-12 % or FPG > 16.7 mmol/L. After resolving glucotoxicity, the regimen can be simplified subsequently.
AACE Guideline
The AACE guideline for initiation of diabetes treatment, along with lifestyle it is based on HbA1c. If initial A1c<7.5 % start monotherapy with any drug but preferably metformin if not contraindicated. But if A1c> 7.5 % start 2-3 drugs like LS+Met+DPP4i. SU or non-SU are considered last as initial therapy. Rather if 3 drugs are to start, it is better to consider one basal insulin or GLP-1RA (Liraglutide, Albiglutideetc). If HbA1c> 9.0% and patient is symptomatic (Classical), it is better to start insulin ±other agents.
IDF Guideline
According to IDF in T2DM, metformin should be the first choice, if contraindicated SU can be started. Choice at 2 nd line may be according to individual need and acceptable from SU, AGI, DPP4i TZD etc. Finally basal or premixed insulin can be initiated as 3 rd line with OAD. Maximum 3 OAD can be used of different mechanism of action. So, considering all issues of pathophysiology,specially of T2DM, as initial treatment when monotherapy is practical, start with metformin along with lifestyle. But few of them will require dual therapy as initial treatment. Choice of second agent is very vital. It needs scientific data and also experience. More than 3 oral drugs should not be practiced. It is better to initiate insulin (basal or premixed once daily) earlier.
Methods
From January to December2014, 1745 newly detected clinically T2DM, who were prescribed their first treatment was recorded (Initiation of diabetes treatment). Data were recorded from each prescription for age, sex, height, weight, BMI, fasting plasma glucose (FPG), 2-h post glucose (as part of OGTT). The names of the drugs as generic (oral or insulin or combination) were recorded.
Prescribed treatment was compared with ADA/EASD algorithm published in January 2015. All the prescriptions were done by physicians working in this field for >5 years. All consecutive prescriptions of "new case, first prescription" were recorded.
The data were analyzed by using SPSS for windows 16 software package. Values were expressed as a percentage of each group or as mean±SE, unless otherwise stated. Chi square test (x 2 ) or Fisher exact test were used for the comparison of qualitative data. Spearman correlation (for non parametric data) or Pearson correlation (for parametric data) were used to establish correlation. Results were considered statistically significant at P<0.05.
Results
Total 1745 prescriptions were analyzed. Females were 1032 (59.15%) and males 713 (40.85%). Base-line characteristics are presented in table I. But, in this study group, most of the cases of newly detected T2DM, treatment was started with 2 drugs Met+SU or Met+DPP4i (63%). Insulin was given mostly based on FPG ( If >14-16 mmol/L), not HbA1c. HbA1c was tested in 13.4 % patients only and serum creatinine was tested only in 16% subjects at diagnosis and up to initiation of treatment. In most groups, definite guideline was not followed, neither FPG nor HbA1c dependent guidelines. Regarding treatment initiation, most patients experienced monotherapy or combination therapy. May be, many of our patients diagnosed late and Met monotherapy will not suffice to achieve the target. Further controlled trials may give the correct answer of the questions.
Regarding initiation with insulin, the first guideline advocated for start with basal insulin once daily with OAD and gradually intensify according to need. But, now-a-days, in guidelines either basal or premixed, preferably analogue can be started as once daily basis. The OAD should be continued with once daily insulin. But, when twice daily insulin is started or intensification is done, it is better to keep only Met or insulin sensitizers with insulin.
Like our observations, many reports showed that these established guidelines are not properly followed. 12, 13 Conclusion From the current survey, it can be concluded that, the well accepted guidelines are not properly followed in newly detected T2DM subjects. Prescribers should be aware of the situation, however every patient is different, so, every aspects of a patient including co-morbidities should be taken in to account before prescribing. Clinician should be aware of guidelines and guidelines guides primary care physician. 
